Publisert 05.07.2021

Regenics - changes Management and Board

July 5th 2021: Regenics appoints new CEO and chairman BoD.

        

Karl Bryn, CEO.    Jan Alfheim, Chair BoD.

 

New Board: The Ordinary General Assembly June 16 th 2021 elected Jan Alfheim as Regenics AS new chairman of the Board. Jan is at present CEO of OncoInvent AS. The other members of the Board was reelected.

Tore Heldrup Rasmussen, reelected

Harald Nordal, reelected

Runhild Gamelsæther, reelected

 

New CEO:

On July 1st 2021 Henrik Lund stepped down as CEO to pursue other activities. July 5th 2021 Karl Bryn, MD accepted the position as new CEO of Regenics AS, starting December 1st 2021.

For more info, contact chairman Jan Alfheim

Board 2021

Management 2021

 

Regenics AS have developed clinical proof of efficacy and safety  in human 2 degree burn wounds for our products Collex® and Vernex®.

The procudts are beeing developed as class III devices. WoundClear® is developed as a BLA/EU CP biotech drug.